WO2002092814A3 - Screening method for attenuating or virulence defective microbial cells - Google Patents

Screening method for attenuating or virulence defective microbial cells Download PDF

Info

Publication number
WO2002092814A3
WO2002092814A3 PCT/EP2002/005493 EP0205493W WO02092814A3 WO 2002092814 A3 WO2002092814 A3 WO 2002092814A3 EP 0205493 W EP0205493 W EP 0205493W WO 02092814 A3 WO02092814 A3 WO 02092814A3
Authority
WO
WIPO (PCT)
Prior art keywords
virulence
attenuating
screening method
microbial cells
identification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/005493
Other languages
French (fr)
Other versions
WO2002092814A2 (en
Inventor
Elke Freissler
Thilo M Fuchs
Heide S Niesalla
Heiko Apfel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CREATOGEN AG
Original Assignee
CREATOGEN AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CREATOGEN AG filed Critical CREATOGEN AG
Priority to US10/477,993 priority Critical patent/US20040152099A1/en
Priority to DE60216099T priority patent/DE60216099D1/en
Priority to EP02743053A priority patent/EP1407014B1/en
Publication of WO2002092814A2 publication Critical patent/WO2002092814A2/en
Anticipated expiration legal-status Critical
Publication of WO2002092814A3 publication Critical patent/WO2002092814A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

This invention relates to a novel method for the genome saturating identification of nucleic acid sequences which are essential for infectivity and/or intracellular survival and/or propagation in permissive eukaryotic host cells, in particular microbial sequences. Further, a method for the identification of attenuated microorganisms and novel antimicrobial compounds using the identified essential nucleic acids and proteins encoded thereby is provided.
PCT/EP2002/005493 2001-05-17 2002-05-17 Screening method for attenuating or virulence defective microbial cells Ceased WO2002092814A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/477,993 US20040152099A1 (en) 2001-05-17 2002-05-17 Screening method for attenuating or virulence defective microbial cells
DE60216099T DE60216099D1 (en) 2001-05-17 2002-05-17 METHOD FOR DETECTING WEAKENED OR VIRULENT-DEFECTIVE MICROBES
EP02743053A EP1407014B1 (en) 2001-05-17 2002-05-17 Screening method for attenuating or virulence defective microbial cells

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP01112158.9 2001-05-17
EP01112158 2001-05-17
EP01117866 2001-07-23
EP01117866.2 2001-07-23

Publications (2)

Publication Number Publication Date
WO2002092814A2 WO2002092814A2 (en) 2002-11-21
WO2002092814A3 true WO2002092814A3 (en) 2004-01-22

Family

ID=26076587

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/005493 Ceased WO2002092814A2 (en) 2001-05-17 2002-05-17 Screening method for attenuating or virulence defective microbial cells

Country Status (5)

Country Link
US (1) US20040152099A1 (en)
EP (1) EP1407014B1 (en)
AT (1) ATE345386T1 (en)
DE (1) DE60216099D1 (en)
WO (1) WO2002092814A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7390620B2 (en) 2001-04-06 2008-06-24 Creatogen Laboratories Gmbh Screening method for anti-microbial drug targets by genome-saturating mutagenesis (GSM)
SE0300413D0 (en) * 2003-02-15 2003-02-15 Innate Pharmaceuticals Ab Methods to identify new virulence-associated genes

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986001829A1 (en) * 1984-09-12 1986-03-27 Scripps Clinic And Research Foundation A vaccine utilizing an avirulent strain of a microbial pathogen
US5434065A (en) * 1993-05-06 1995-07-18 President And Fellows Of Harvard College In vivo selection of microbial virulence genes
WO1996017951A2 (en) * 1994-12-09 1996-06-13 Rpms Technology Limited Identification of genes responsible for in vivo survival of microorganisms
WO1999037330A1 (en) * 1998-01-21 1999-07-29 Smithkline Beecham Corporation Method for determining gene essentiality in a pathogen
WO1999050402A1 (en) * 1998-03-27 1999-10-07 President And Fellows Of Harvard College Systematic identification of essential genes by in vitro transposon mutagenesis
WO2000014240A2 (en) * 1998-09-04 2000-03-16 Creatogen Aktiengesellschaft Attenuated salmonella sp12 mutants as antigen carriers
WO2000073336A1 (en) * 1999-05-28 2000-12-07 Sbl Vaccin Ab Fimbrial proteins
WO2000073502A2 (en) * 1999-05-31 2000-12-07 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Essential genes and gene products for identifying, developing and optimising immunological and pharmacological active ingredients for the treatment of microbial infections
WO2001002555A1 (en) * 1999-07-06 2001-01-11 Institut Pasteur Method of making and identifying attenuated microorganisms, compositions utilizing the sequences responsible for attenuation, and preparations containing attenuated microorganisms
WO2002083940A2 (en) * 2001-04-06 2002-10-24 Creatogen Aktiengesellschaft Screening method for anti-microbial drug targets by genome-saturing mutagenesis (gsm)

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986001829A1 (en) * 1984-09-12 1986-03-27 Scripps Clinic And Research Foundation A vaccine utilizing an avirulent strain of a microbial pathogen
US5434065A (en) * 1993-05-06 1995-07-18 President And Fellows Of Harvard College In vivo selection of microbial virulence genes
WO1996017951A2 (en) * 1994-12-09 1996-06-13 Rpms Technology Limited Identification of genes responsible for in vivo survival of microorganisms
WO1999037330A1 (en) * 1998-01-21 1999-07-29 Smithkline Beecham Corporation Method for determining gene essentiality in a pathogen
WO1999050402A1 (en) * 1998-03-27 1999-10-07 President And Fellows Of Harvard College Systematic identification of essential genes by in vitro transposon mutagenesis
WO2000014240A2 (en) * 1998-09-04 2000-03-16 Creatogen Aktiengesellschaft Attenuated salmonella sp12 mutants as antigen carriers
WO2000073336A1 (en) * 1999-05-28 2000-12-07 Sbl Vaccin Ab Fimbrial proteins
WO2000073502A2 (en) * 1999-05-31 2000-12-07 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Essential genes and gene products for identifying, developing and optimising immunological and pharmacological active ingredients for the treatment of microbial infections
WO2001002555A1 (en) * 1999-07-06 2001-01-11 Institut Pasteur Method of making and identifying attenuated microorganisms, compositions utilizing the sequences responsible for attenuation, and preparations containing attenuated microorganisms
WO2002083940A2 (en) * 2001-04-06 2002-10-24 Creatogen Aktiengesellschaft Screening method for anti-microbial drug targets by genome-saturing mutagenesis (gsm)

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CLAUS H ET AL: "Identification of a hotspot for transformation of Neisseria meningitidis by shuttle mutagenesis using signature-tagged transposons", MOLECULAR AND GENERAL GENETICS, SPRINGER VERLAG, BERLIN, DE, vol. 259, no. 4, 1998, pages 363 - 371, XP002175425, ISSN: 0026-8925 *
FIELDS P I ET AL: "MUTANTS OF SALMONELLA-TYPHIMURIUM THAT CANNOT SURVIVE WITHIN THE MACROPHAGE ARE AVIRULENT", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 83, no. 14, 1986, 1986, pages 5189 - 5193, XP002241678, ISSN: 0027-8424 *
HENSEL M ET AL: "WHOLE GENOME SCAN FOR HABITAT-SPECIFIC GENES BY SIGNATURE-TAGGED MUTAGENESIS", ELECTROPHORESIS, WEINHEIM, DE, vol. 19, no. 4, April 1998 (1998-04-01), pages 608 - 612, XP001085303, ISSN: 0173-0835 *
MAHAN M J ET AL: "SELECTION OF BACTERIAL VIRULENCE GENES THAT ARE SPECIFICALLY INDUCED IN HOST TISSUES", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 259, 29 January 1993 (1993-01-29), pages 686 - 688, XP001026153, ISSN: 0036-8075 *
POLISSI ALESSANDRA ET AL: "Large-scale identification of virulence genes from Streptococcus pneumoniae", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 66, no. 12, December 1998 (1998-12-01), pages 5620 - 5629, XP002136502, ISSN: 0019-9567 *

Also Published As

Publication number Publication date
EP1407014B1 (en) 2006-11-15
DE60216099D1 (en) 2006-12-28
ATE345386T1 (en) 2006-12-15
US20040152099A1 (en) 2004-08-05
EP1407014A2 (en) 2004-04-14
WO2002092814A2 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
AU2003240327A1 (en) Composition and methods for obtaining nucleic acids from sputum
WO2002090539A3 (en) Compositions, methods, and kits for isolating nucleic acids using surfactants and proteases
WO2003008611A3 (en) Process for the preparation of l-amino acids using strains of the enterobacteriaceae family which contain an enhanced talb gene
WO2002059300A3 (en) Double-stranded rna-mediated gene suppression
WO2003008616A3 (en) PROCESS FOR THE PREPARATION OF L-AMINO ACIDS USING STRAINS OF THE ENTEROBACTERIACEAE FAMILY WHICH CONTAIN AN ATTENUATED aceK GENE
WO2003004659A8 (en) Recombination systems and a method for removing nucleic acid sequences from the genome of eukaryotic organisms
AU2001244677A1 (en) Method of amplifying nucleic acid by using double-stranded nucleic acid as template
WO2003068926A3 (en) Over-expression of extremozyme genes in pseudomonads and closely related bacteria
WO2001098509A3 (en) Grain processing method and transgenic plants useful therein
WO1999033960A3 (en) Proteases from gram positive organisms
WO2003060077A3 (en) Endothelial stem cells, populations, methods of isolation and use thereof
ATE452187T1 (en) METHOD FOR ISOLATION OF NUCLEIC ACIDS
WO2005064019A3 (en) Universal amplification of fragmented rna
WO2005058945A3 (en) Gene variants coding for proteins from the metabolic pathway of fine chemicals
EP2327722A3 (en) Mammalian genes involved in viral infection and tumor suppression
WO2002092814A3 (en) Screening method for attenuating or virulence defective microbial cells
WO2001072974A3 (en) L-galactose dehydrogenase from arabidopsis thaliana, and uses thereof
WO2002086112A3 (en) Nucleic acid molecules encoding starch degrading enzymes
WO2003016550A3 (en) Compositions and methods comprising control nucleic acid
WO2004072225A3 (en) Transgenic fungi expressing bcl-2 and methods of using bcl-2 or portions thereof for improving biomass production, survival, longevity, stress resistance and pathogenicity of fungi
WO2002101064A3 (en) Process for the preparation of d-pantothenic acid and/or salts thereof
WO2002068682A3 (en) Method for identifying biologically active structures of microbial pathogens
WO2002062964A3 (en) Ap1 amine oxidase variants
WO2003047532A3 (en) Compositions and methods for the therapeutic use of an atonal-associated sequence for a gastrointestinal condition
WO2003008568A3 (en) Culture medium for cultivation of filamentous fungi

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10477993

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002743053

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002743053

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWG Wipo information: grant in national office

Ref document number: 2002743053

Country of ref document: EP